

Redline version  
compares Second edition to  
First edition



---

---

## Cardiovascular implants — Cardiac valve prostheses —

### Part 3: Heart valve substitutes implanted by transcatheter techniques

*Implants cardiovasculaires — Prothèses valvulaires —*

*Partie 3: Valves cardiaques de substitution implantées par des  
techniques transcathéter*

iTeh Standards  
(<https://standards.iteh.ai>)  
Document Preview

[ISO 5840-3:2021](https://standards.iteh.ai/catalog/standards/iso/deade5fc-b621-4c56-9651-b13230074310/iso-5840-3-2021)

<https://standards.iteh.ai/catalog/standards/iso/deade5fc-b621-4c56-9651-b13230074310/iso-5840-3-2021>



Reference number  
ISO 5840-3:redline:2021(E)

© ISO 2021

## IMPORTANT

This marked-up version uses the following colour-coding:

- Text example 1 — Text has been added (in green)
- ~~Text example 2~~ — Text has been deleted (in red)
- Graphic figure has been added
- Graphic figure has been deleted
- 1.x ... — If there are changes in a clause/subclause, the corresponding clause/subclause number is highlighted in yellow in the Table of contents

## DISCLAIMER

This marked-up version highlights the main changes in this edition of the document compared with the previous edition. It does not focus on details (e.g. changes in punctuation).

This marked-up version does not constitute the official ISO document and is not intended to be used for implementation purposes.

*ITeH Standards*  
*(<https://standards.iteh.ai>)*  
*Document Preview*

[ISO 5840-3:2021](https://standards.iteh.ai/catalog/standards/iso/deade5fc-b621-4c56-9651-b13230074310/iso-5840-3-2021)

<https://standards.iteh.ai/catalog/standards/iso/deade5fc-b621-4c56-9651-b13230074310/iso-5840-3-2021>



## COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office  
CP 401 • Ch. de Blandonnet 8  
CH-1214 Vernier, Geneva  
Phone: +41 22 749 01 11  
Fax: +41 22 749 09 47  
Email: [copyright@iso.org](mailto:copyright@iso.org)  
Website: [www.iso.org](http://www.iso.org)

Published in Switzerland

# Contents

Page

<b>Foreword</b>	v
<b>Introduction</b>	vi
<b>1 Scope</b>	1
<b>2 Normative references</b>	1
<b>3 Terms and definitions</b>	3
<b>4 Abbreviations</b>	11
<b>5 Fundamental requirements</b>	12
<b>6 Device description</b>	12
6.1 <del>Intended use</del> General	12
6.2 Intended use	12
<del>6.2</del> 6.3 Design inputs	12
<del>6.2.1</del> 6.3.1 Operational specifications	12
<del>6.2.2</del> 6.3.2 Performance specifications	14
<del>6.2.3</del> 6.3.3 Implant procedure	15
<del>6.2.4</del> 6.3.4 Packaging, labelling and sterilization	15
<del>6.3</del> 6.4 Design outputs	16
<del>6.4</del> 6.5 Design transfer (manufacturing verification/validation)	16
<del>6.5</del> 6.6 Risk management	16
<b>7 Design verification testing and analysis/design and validation</b>	16
7.1 General requirements	16
7.2 <i>In vitro</i> assessment	17
7.2.1 General	17
<del>7.2.1</del> 7.2.2 Test conditions, sample selection and reporting requirements	17
<del>7.2.2</del> 7.2.3 Material property assessment	18
<del>7.2.3</del> 7.2.4 <del>Device hydrodynamic</del> Hydrodynamic performance assessment	19
<del>7.2.4</del> 7.2.5 Structural performance assessment	21
<del>7.2.5</del> 7.2.6 <del>Additional implant design evaluation requirements</del> Design- or procedure-specific testing	23
<del>7.2.6</del> 7.2.7 <del>Delivery system design evaluation requirements</del> Device MRI compatibility	25
<del>7.2.7</del> Design specific testing	27
<del>7.2.8</del> Visibility	27
<del>7.2.9</del> 7.2.8 Simulated use	27
7.2.9 Human factors and usability assessment	27
7.2.10 <del>Human factors/usability</del> Implant thrombogenic and haemolytic potential assessment	27
7.3 Preclinical <i>in vivo</i> evaluation	28
7.3.1 General	28
<del>7.3.1</del> 7.3.2 Overall requirements	28
<del>7.3.2</del> 7.3.3 Methods	30
<del>7.3.3</del> 7.3.4 Test report	31
7.4 Clinical investigations	31
7.4.1 General	31
7.4.2 Study considerations	33
7.4.3 Study endpoints	35
7.4.4 Ethical considerations	35
7.4.5 Pivotal studies: Distribution of subjects and investigators	35
<del>7.4.2</del> 7.4.6 Statistical considerations including sample size and duration	36
<del>7.4.3</del> 7.4.7 <del>Distribution of subjects and investigators</del> Patient selection criteria	38
<del>7.4.4</del> 7.4.8 <del>Sample size</del> Valve thrombosis prevention	39
<del>7.4.5</del> Entry criteria	39
<del>7.4.6</del> Duration of the study	39

7.4.7	7.4.9	Clinical data requirements	40
7.4.8		Clinical investigation report	44
<del>Annex A (informative) Rationale for the provisions of this part of ISO 5840</del>			<del>46</del>
<del>Annex B (informative) Examples of transcatheter heart valve substitutes, components and delivery systems</del>			<del>49</del>
<del>Annex C (normative) Packaging</del>			<del>53</del>
<del>Annex D (normative) Product labels, instructions for use and training</del>			<del>54</del>
<del>Annex E (normative) Sterilization</del>			<del>57</del>
Annex FA	(informative)	<del>Valve description</del> Description of the transcatheter heart valve system	58
Annex GB	(informative)	Transcatheter heart valve substitute <del>hazards, associated failure modes and evaluation methods</del> hazard analysis example	60
<del>Annex H (informative) In vitro test guidelines for paediatric devices</del>			<del>65</del>
<del>Annex I (informative) Statistical procedures when using performance criteria</del>			<del>69</del>
<del>Annex J (informative) Examples and definitions of some physical and material properties of transcatheter heart valve substitutes and their components</del>			<del>70</del>
<del>Annex K (informative) Examples of standards applicable to testing of materials and components of transcatheter heart valve substitutes</del>			<del>82</del>
<del>Annex L (informative) Raw and post conditioning mechanical properties for support structure materials</del>			<del>88</del>
<del>Annex M (informative) Corrosion assessment</del>			<del>90</del>
Annex NC	(informative)	Guidelines for verification of hydrodynamic performance — Pulsatile flow testing	93
<del>Annex O (informative) Durability testing</del>			<del>103</del>
Annex PD	(informative/normative)	<del>Fatigue assessment</del> Requirements for delivery system design and evaluation	105
<del>Annex E (informative) Examples of design specific testing</del>			<del>112</del>
Annex QF	(informative)	Preclinical <i>in vivo</i> evaluation	114
<del>Annex RG (normative) Adverse event classification during clinical investigation</del>			<del>117</del>
Annex SH	(informative)	<del>Echocardiographic protocol</del> Multimodality imaging of TAVI and TMVI pre, peri and post-implantation assessments — Examples	125
<del>Bibliography</del>			<del>131</del>

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

~~International Standards are~~ The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the ~~rules given in~~ editorial rules of the ISO/IEC Directives, Part 2 (see [www.iso.org/directives](http://www.iso.org/directives)).

~~The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.~~

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see [www.iso.org/patents](http://www.iso.org/patents)).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see [www.iso.org/iso/foreword.html](http://www.iso.org/iso/foreword.html).

~~ISO 5840-3~~ This document was prepared by Technical Committee ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 285, *Non-active surgical implants*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

This second edition cancels and replaces the first edition (ISO 5840-3:2013), which has been technically revised.

The main changes compared to the previous edition are as follows: the engineering and clinical requirements in the ISO 5840 series have been updated to current specifications and integrated and harmonized across all parts.

A list of all parts in the ISO 5840 series ~~consists of the following parts, under the general title~~ can be found on the ~~Cardiovascular implants – Cardiac valve prostheses~~ ISO website.

~~Part 3: Heart valve substitutes implanted by minimally invasive techniques~~

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at [www.iso.org/members.html](http://www.iso.org/members.html).

## Introduction

No heart valve substitute is ideal. Therefore, a group of engineers, scientists and clinicians well aware of the problems associated with transcatheter heart valve substitutes and their development has prepared this part of ISO 5840. In several areas, the provisions of this part of ISO 5840 have been deliberately left partially defined so as not to inhibit development and innovation. This part of ISO 5840 specifies types of tests, test methods and requirements for test apparatus. It requires documentation of test methods and results. This part of ISO 5840 deals with those areas that will ensure adequate mitigation of device associated risks for patients and other users of the device, facilitate quality assurance, aid the cardiac surgeon and cardiologist in choosing a heart valve substitute, and ensure that the device will be presented in a convenient form. This part of ISO 5840 emphasizes the need to specify types of *in vitro* testing, preclinical *in vivo* and clinical evaluations as well as to report, reporting of all *in vitro*, preclinical *in vivo*, and clinical evaluations. It describes the labels and labelling and packaging of the device. Such a process involving *in vitro*, preclinical *in vivo* and clinical evaluations is intended to clarify the required procedures prior to market release and to enable prompt identification and management of any subsequent problems/issues.

With regard to *in vitro* testing and reporting, apart from basic material testing for mechanical, physical, chemical and biocompatibility characteristics, this part of ISO 5840 also covers important hydrodynamic and durability characteristics of transcatheter heart valve substitutes and their delivery systems. This part of ISO 5840 does not specify exact test methods for hydrodynamic and durability testing but it offers guidelines for the test apparatus.

This part of ISO 5840 should be revised, updated and amended as knowledge and techniques in heart valve substitute technology improve.

This part of ISO 5840 document is to be used in conjunction with ISO 5840:2005-1, which will be replaced by and ISO 5840-12 in future.

ISO 5840-3:2021

<https://standards.iteh.ai/catalog/standards/iso/deade5fc-b621-4c56-9651-b13230074310/iso-5840-3-2021>

# Cardiovascular implants — Cardiac valve prostheses —

## Part 3: Heart valve substitutes implanted by transcatheter techniques

### 1 Scope

This document is applicable to all devices intended for implantation as a transcatheter heart valve substitute.

This document is applicable to transcatheter heart valve substitutes and to the accessory devices, packaging and labelling required for their implantation and for determining the appropriate size of heart valve substitute to be implanted.

This ~~part of ISO 5840 outlines~~ document establishes an approach for verifying/validating the design and manufacture of a transcatheter heart valve substitute through risk management. The selection of appropriate verification/validation tests and methods are to be derived from the risk assessment. The tests can include those to assess the physical, chemical, biological and mechanical properties of heart valve substitutes and of their materials and components. The tests can also include those for preclinical *in vivo* evaluation and clinical evaluation of the finished heart valve substitute.

This ~~part of ISO 5840~~ document defines operational conditions and performance requirements for transcatheter heart valve substitutes where adequate scientific and/or clinical evidence exists for their justification.

This ~~part of ISO 5840 is applicable to all devices intended for implantation in human hearts as~~ document includes considerations for implantation of a transcatheter heart valve substitute inside a pre-existing prosthetic device (e.g. valve-in-valve and valve-in-ring configurations).

~~This part of ISO 5840 is applicable to both newly developed and modified transcatheter heart valve substitutes and to the accessory devices, packaging and labelling required for their implantation and for determining the appropriate size of heart valve substitute to be implanted.~~

~~This part of ISO 5840 excludes heart valve substitutes designed for implantation in artificial hearts or heart assist devices.~~

~~This part of ISO 5840 excludes valve-in-valve configurations and homografts.~~

~~This part of ISO 5840 does not specifically address non-traditional surgically implanted heart valve substitutes (e.g. sutureless). For these devices, the requirements of both this part of ISO 5840 and ISO 5840:2005 might be relevant and can be considered.~~

~~NOTE A rationale for the provisions of this part of ISO 5840 is given in Annex A.~~

### 2 Normative references

The following ~~referenced~~ documents are ~~indispensable for the application of~~ referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

~~ISO 10993-5840-1:2021, Biological evaluation of medical devices Cardiovascular implants — Cardiac valve prostheses — Part 1: Evaluation and testing within a risk management process General requirements~~